CVD Share Price

Open 107.12 Change Price %
High 107.39 1 Day -0.71 -0.66
Low 106.42 1 Week 0.00 0.00
Close 106.42 1 Month 0.00 0.00
Volume 13373932 1 Year 0.00 0.00
52 Week High 34.91
52 Week Low 0.00
CVD Important Levels
Resistance 2 107.32
Resistance 1 106.95
Pivot 106.74
Support 1 105.89
Support 2 105.52
NYSE USA Most Active Stocks
BAC 23.09 0.61%
BAC 23.09 0.61%
BAC 23.09 0.61%
EMC 29.05 0.97%
EMC 29.05 0.97%
EMC 29.05 0.97%
PCS 11.84 -0.92%
PCS 11.84 -0.92%
PCS 11.84 -0.92%
AMD 10.34 0.00%
More..
NYSE USA Top Gainers Stocks
INVN 10.55 27.57%
POM 26.93 26.79%
POM 26.93 26.79%
EBS 32.37 18.92%
EBS 32.37 18.92%
SWC 17.32 17.98%
SWC 17.32 17.98%
PACD 5.33 17.40%
SDLP 4.48 16.06%
UTI 3.55 14.15%
More..
NYSE USA Top Losers Stocks
ENL 15.81 -66.25%
ENL 15.81 -66.25%
ENL 15.81 -66.25%
OIBR 0.17 -43.33%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
More..

Covance Inc. (NYSE: CVD)

CVD Technical Analysis 5
As on 18th Feb 2015 CVD Share Price closed @ 106.42 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 92.65 & Strong Buy for SHORT-TERM with Stoploss of 104.94 we also expect STOCK to react on Following IMPORTANT LEVELS.
CVD Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
CVD Other Details
Segment EQ
Market Capital 3019919616.00
Sector Healthcare
Industry Medical Laboratories & Research
Offical website http://www.covance.com
CVD Address
CVD
210 Carnegie Center
Princeton, NJ 08540
United States
Phone: 609-452-4440
Fax: 609-452-9375
CVD Latest News
Interactive Technical Analysis Chart Covance Inc. ( CVD NYSE USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Covance Inc.
CVD Business Profile
Covance Inc., a drug development services company, provides a range of early-stage and late-stage product development services to the pharmaceutical and biotechnology industries worldwide. It operates in two segments, Early Development and Late-Stage Development. The Early Development segment offers preclinical services, such as toxicology, pharmaceutical chemistry, nutritional chemistry and food safety, purpose-bred animals for biomedical research, lead optimization and translational services, and bioanalytical testing services. This segment also provides clinical pharmacology services, including first-in-human trials and early patient proof of concept studies of new pharmaceuticals at its clinics in the United States and the United Kingdom. The Late-Stage Development segment offers central laboratory services to biotechnology and pharmaceutical customers; and clinical development services, such as the full management of Phase II through IV clinical studies, study design and modeling, co-ordination of study activities, trial logistics, monitoring of study site performance, clinical data management and biostatistical analysis, and medical writing and regulatory services, as well as periapproval services. This segment also provides market access services, including reimbursement and healthcare economics consulting services, which comprise outcomes and pharmacoeconomic studies, reimbursement planning, reimbursement advocacy programs, risk evaluation and mitigation strategy services, registry services, specialty pharmacy services, and managed market contracting services; and clinical trial support services, such as interactive voice and Web response, and cardiac safety services. The company also provides laboratory testing services to the chemical, agrochemical, and food industries. Covance Inc. was founded in 1987 and is headquartered in Princeton, New Jersey.